Patents by Inventor Mark Selby

Mark Selby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160141692
    Abstract: The present invention is concerned with improved fuel cell systems and methods.
    Type: Application
    Filed: June 20, 2014
    Publication date: May 19, 2016
    Applicant: Ceres Intellectual Property Company Limited
    Inventors: Paul BARNARD, Mark SELBY, Andrew HAZELL, Christopher John EVANS
  • Patent number: 8580259
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: November 12, 2013
    Assignee: Medarex, L.L.C.
    Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
  • Patent number: 8563694
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 22, 2013
    Assignees: Medarex, Inc., N.V.Organon
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Publication number: 20120310720
    Abstract: An approach is provided for processing promotional information for facilitating a point-of-sales transaction via radio frequency (RF) memory tags. A platform causes, at least in part, a capture of promotional information from a radio frequency memory tag associated with a merchant. The tags are placed at locations including a point-of-sales terminal, store entrance or near a poster to facilitate customer access. The platform processes and/or facilitates a processing of the promotional information to present one or more offers at a device, and receives an input for selecting at least one of the one or more offers for redemption. In response, the platform causes, at least in part, a validation of the redemption of at least one of the one or more offers. The platform then causes, at least in part, a presentation of the validation at the device for a confirmation by the merchant.
    Type: Application
    Filed: March 30, 2012
    Publication date: December 6, 2012
    Applicant: Nokia Corporation
    Inventors: Damien Balsan, Ismo Tapio Hautala, Mark Selby, Tapio Mika Kalevi Tolvanen, Zahid N. Ahmed
  • Publication number: 20120288500
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 15, 2012
    Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
  • Publication number: 20120269840
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 25, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan W. BARNETT, Jan ZUR MEGEDE, Indresh SRIVASTAVA, Ying LIAN, Karin HARTOG, Hong LIU, Catherine GREER, Mark SELBY, Christopher WALKER
  • Patent number: 8247537
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: August 21, 2012
    Assignee: Medarex, Inc.
    Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
  • Publication number: 20120183565
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: July 26, 2010
    Publication date: July 19, 2012
    Applicants: N.V. ORGANON, MEDAREX, INC.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Patent number: 8168418
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 1, 2012
    Inventors: Susan W Barnett, Jan Zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
  • Publication number: 20120100573
    Abstract: Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
    Type: Application
    Filed: October 21, 2010
    Publication date: April 26, 2012
    Inventors: Kent B. THUDIUM, Mark Selby
  • Publication number: 20110312260
    Abstract: A chimney cap provides not only protective features of conventional chimney caps, but may also provide energy production. The chimney cap may include one or more wind turbines that may capture wind energy and, with associated generators, may convert the wind energy to electricity. The chimney cap may also include one or more solar panels which may capture solar energy and convert that energy into electricity. A control box may receive the electricity from the generators and the solar panels and may provide the energy to a home, business, a storage device, the electric grid, or the like.
    Type: Application
    Filed: May 31, 2011
    Publication date: December 22, 2011
    Inventors: DARREL COX, STUART POTTER, MARK SELBY, ROGER FROSINI
  • Publication number: 20110182904
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2.
    Type: Application
    Filed: September 5, 2007
    Publication date: July 28, 2011
    Inventors: Deborah Zimmerman, Mark Selby, Mohan Srinivasan, Alasdair Bell, Sujata Singh, Richard Theolis, Heidi N. Leblanc, Kyra D. Zens, Timothy William Sproul
  • Publication number: 20110159039
    Abstract: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.
    Type: Application
    Filed: August 30, 2010
    Publication date: June 30, 2011
    Inventors: Michael Houghton, Mark Selby, Sergio Abrignani, Jens Martin Heile, Derek O'Hagan
  • Publication number: 20110150892
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen- specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: August 11, 2009
    Publication date: June 23, 2011
    Inventors: Kent B. Thudium, Mark Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. LeBlanc
  • Publication number: 20110065146
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Application
    Filed: April 30, 2010
    Publication date: March 17, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Susan W. Barnett, Jan zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
  • Patent number: 7888004
    Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 15, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
  • Patent number: 7846687
    Abstract: Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: December 7, 2010
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Kent B. Thudium, Mark Selby
  • Publication number: 20100172900
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
    Type: Application
    Filed: November 15, 2007
    Publication date: July 8, 2010
    Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
  • Patent number: 7718401
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: May 18, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Susan W. Barnett, Jan zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
  • Publication number: 20090130762
    Abstract: The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
    Type: Application
    Filed: October 17, 2007
    Publication date: May 21, 2009
    Inventors: Xavier Paliard, Michael Houghton, Mark Selby